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Abstract
Background: Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver
resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate.
The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if
quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR
function, measured against indocyanine green (ICG) liver function test.
Methods: HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or
more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing.
Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver
remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15
compared to GC of whole liver (WL-GC) as a secondary outcome.
Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-
variate analysis to the value of functional MRI and derive multivariant prediction models for future validation.
Discussion: If successful, this test will potentially provide an efficient means to quantitatively assess FLR function
and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and
thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added
benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden
on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance
Imaging - Full Text View - ClinicalTrials.gov, n.d.)
Trial registration: ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 – Retrospectively
registered
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Background
The liver is the most common site of metastases in pa-
tients with colorectal cancer (CRC). Up to two thirds of
CRC patients go on to develop liver metastasis during
the course of their disease and 18% actually presents
with liver metastasis at their first consultation [1–3]..
Primary liver cancers are the fifth most commonly oc-
curring cancer in men and the ninth in women world-
wide with 840,000 new cases diagnosed in 2018 alone
[4]. This includes mainly two types of cancer: hepatocel-
lular carcinomas (HCC), often associated with chronic
liver disease and cholangiocarcinomas (CCA), tumours
of the biliary tree that most commonly occur in the peri-
hilar region of the liver, but also within the liver paren-
chyma and as a result require extensive resections.
Whilst several treatment modalities exist the only
curative option for these patients is surgical resection
ranging from minor parenchymal preserving metasta-
sectomy to major liver resection removing up to 75% of
the liver. The latter group is technically challenging and
associated with significant risks and complications; po-
tentially the most serious of these being post-
hepatectomy liver failure or PHLF [5] which can ultim-
ately result in death. PHLF occurs in 5–10% of patients
undergoing major hepatectomy due to inability of the
remnant liver to maintain its synthetic, excretory, and
detoxifying functions and not regenerate at a sufficient
pace. PHLF ranges in severity from transient hepatic in-
sufficiency while the liver regenerates to full-blown ful-
minant hepatic failure [6–8]. The latter group is
associated with a high risk of mortality of up to 54% [9].
Preoperative methods used to reduce such risk include
portal vein embolisation (PVE) of the part of the liver to
be removed in future surgery. PVE will result in divert-
ing blood flow to the contralateral side and subsequent
hypertrophy of the liver remnant (May and Madoff
2012). A second alternative is to perform the operation
over two stages which often involves clearing of tu-
mour(s) on one side and ligating the portal vein branch
to other side at first stage followed by second stage after
several weeks to remove the part of liver that has atro-
phied. Alternatively, a similar outcome can be achieved
via an open surgical procedure called ALPPS (associating
liver partition and portal vein ligation in staged hepatec-
tomy). ALPPS involves two operations that are spaced in
a shorter time interval. All of these techniques are asso-
ciated with increased complications of different magni-
tude. PVE, the least invasive carries risk of some
morbidity and failure to induce hypertrophy in a propor-
tion of patients. The two stage operations have increased
morbidity of two operations and ALPPS is associated
with a significant increase in mortality. The risk is high
enough for ALPPS with tumours like Choilangiocarci-
noma at liver hilum that it is currently contraindicated
for these tumours. The risk of failure to induce hyper-
trophy persists with two stage hepatectomy whereas
ALPPS, despite the significantly increased complications
has a higher chance of succeeding in inducing
hypertrophy.
Selection of patients for surgery, precise planning of sur-
gery and assessing the need for interventions to induce
liver hypertrophy would benefit greatly from an accurate
prediction of the function of future liver remnant (FLR)
and assessment of risk of PHLF. Unfortunately, reliable
and reproducible tests to predict function of remnant liver
are currently not available in clinical practice. This results
in either patients being turned down for potentially cura-
tive treatment or patients undergoing multiple interven-
tions with additional risks including mortality when such
interventions are not essential due to adequate function of
remnant liver. Quantitative liver function tests such as in-
docyanine green (ICG), LiMAX (maximum liver function
capacity) assess the liver as whole rather than the function
of different parts of liver. Conventional cross sectional im-
aging like magnetic resonance imaging (MRI) and com-
puterized tomography (CT) can provide an estimate of the
volume of the future remnant, but this is inadequate in
predicting the function in the presence of background
liver disease like fibrosis, chemotherapy related injury, cir-
rhosis and cholestatsis. A potential solution is to combine
whole liver function tests with FLR volume as determined
on imaging ([10]; Y [11].; Yukihiro [12]), but this is based
on an assumption that liver function is uniformly distrib-
uted across all liver segments. Hepatobiliary scintigraphy
accounts for this factor [13–15], but is not widely available
and is limited by inaccurate assessment of volume.
MRI-based liver function tests based on uptake of
the liver-specific contrast agent Gadoxetate offer a
promising approach for assessment of FLR function
in clinical practice [16]. Apart from wide availability,
a major advantage of Gadoxetate as compared to ICG
and tracers used in hepatobiliary scintigraphy is the
low extraction fraction even in healthy liver. With a
fast dynamic acquisition and a pharmacokinetic ana-
lysis of the data (dynamic Gadoxetate-enhanced MRI
or DGE-MRI), this enables a separate quantification
of liver perfusion and hepatocellular function, as well
as structural parameters such as the extracellular vol-
ume fraction [17]. Previous studies on Gadoxetate
MRI for liver surgery planning use descriptive or ap-
proximate measures of Gadoxetate uptake and there-
fore do not fully exploit the potential offered by this
extra quantitative information [18–20]. Moreover, pre-
vious work tends to focus on HCC, but inhomogen-
eous liver function can be relevant even in patients
with liver metastases due to the effects of
chemotherapy-induced liver injury and obesity-
associated liver disease [21].
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A pilot study with DGE-MRI in 29 patients with colo-
rectal liver metastases (CRLM), using post-operative bili-
rubin as a surrogate for liver function, suggested that
DGE-MRI biomarkers significantly improved the predic-
tions of post-operative function compared to biochem-
ical markers and volumetric assessment of the FLR [22].
A parameter of particular interest was the normalised
Gadoxetate clearance (GC), a combination of perfusion
and function that determines the rate at which the liver
clears Gadoxetate from the blood pool. GC has units of
mL/min/kg and measures the volume of plasma (mL)
fully cleared of Gadoxetate per minute and per kg body
weight. Potentially, the GC of the FLR (FLR-GC) can
offer a clear and widely available cut-off value to deter-
mine if a surgery is safe to perform, irrespective of the
underlying disease or the body size of the patient consid-
ered for surgery.
The primary aim of HEPARIM is to determine if
DGE-MRI biomarkers of liver function and perfusion
offer a significant improvement in the prediction of
post-hepatectomy liver function. ICG clearance will be
used as a reference measurement of post-operative liver
function and correlated against DGE-MRI before sur-
gery. As a secondary aim, DGE-MRI will be validated
directly by performing ICG pre-operatively at the same
time as the MRI and correlating the ICG clearance with
whole-liver GC (WL-GC). A positive result on the pri-
mary aim can potentially improve the safety profile of
hepatic surgery and open the door to extend the indica-
tion to wider groups of patients and avoid harmful inter-
ventions where they are not required.
Methods/design
Objectives and outcome measures
Primary objective
To determine if DGE-MRI can improve predictions of
post-hepatectomy liver function. The primary outcome
measure is the correlation between preoperative FLR-
GC (mL/min/kg) and ICG R15 1 day after surgery (%).
Secondary objectives
1. To validate DGE-MRI based measurements of liver
function against a gold-standard liver function test.
The outcome measure is the correlation between
preoperative WL-GC (mL/min/kg) and a simultan-
eously measured ICG R15 (%).
2. To determine the relationship between volumetric
and functional liver growth after PVE/ALPPS.
Outcome measure is the correlation between
growth in FLR volume and growth in FLR-GC after
the first stage.
3. To determine if preoperative DGE-MRI can im-
prove predictions of PHLF (any grade) over and
above routinely available data. HEPARIM will adopt
the PHLF definition by the International Study
Group of Liver Surgery (ISGLS).
4. To determine if preoperative DGE-MRI can im-
prove predictions of 90-day post-operative outcome
over and above routinely available data. (Hepatec-
tomy Risk Assessment With Functional Magnetic




HEPARIM is an observational cohort study that will aim
to recruit 134 patients referred locally for a one- or two-
stage liver resection of 2 segments or more. Participants
will undergo a preoperative ICG liver function test and a
DGE-MRI scan of the liver, and another ICG test at 1
day after surgery. Additional pre- and postoperative data
will be collected from their medical records including
demographics, routine imaging, biochemistry, pathology
and radiology reports, any data collected in the 90-day
follow-up visit. Participants who will undergo a staged
resection with either PVE or ALLPS will have additional
DCE-MRI and ICG tests before the first stage.
Study authorizations
The HEPARIM study has been approved by the North
West - Liverpool Central Research Ethics Committee
(IRAS project ID: IRAS 240787, REC reference: 19/NW/
0139). The study sponsor is University of Leeds.
Setting
A single high-volume tertiary referral hepatobiliary sur-
gery center in the United Kingdom (Leeds Teaching
Hospitals Trust).
Timing
Recruitment was scheduled to occur over a two-year
period which began on 1st July 2019. The timing has
been significantly disrupted due to the ongoing COVID-
19 pandemic, ongoing at the time of writing. Patients
will be followed up for a three-month period post-
operatively. Recruitment will end when the target num-
ber of patients have been recruited and have completed
their imaging, surgery and follow up, or when the re-
search team feel that continuing the study is either un-
safe or unfeasible.
Data analysis
A univariable analysis will be performed comparing pre-
operative MR predictions of post-operative liver function
against post-operative ICG-R15 (primary objective) and
comparing preoperative MR measures of whole liver
function against preoperative ICG-R15 (secondary
Elsharif et al. BMC Cancer         (2021) 21:1139 Page 3 of 10
objective). Second the correlations will be investigated in
a multivariable analysis to determine if MRI adds value
to existing preoperative biomarkers for predicting PHLF
and 90-day outcome. Multivariate models will be derived
for predicting both outcomes and it will then be tested
whether this combined score is statistically significantly
worse when DGE-MRI is removed from the prediction.
In the PVE/ALPPS group, changes in volume will be
correlated with changes in function of the FLR between
pre PVE/pre-ALPPS and post-PVE/post-ALPPS.
Study participants
Inclusion criteria
Adults over 18 years of age and under 80 years
 Referred to the hepatobiliary surgical service at St
James’s Hospital
 Diagnosed with any hepatic tumour
 One of:
 Referred for liver resection of two or more
Couinaud segments by multi-disciplinary team dis-
cussion at Saint James’s Hospital (Primary resection
arm)
 Referred for PVE or ALPPS prior to likely major
hepatectomy by multi-disciplinary team discussion
at Saint James’s Hospital (PVE/ALPPS arm)
Exclusion criteria
 Unable to consent independently
 Previous liver resection
 Private patients
 Concurrent malignancy unrelated to liver tumour
 Chronic renal failure (eGFR < 30 mL/min)
 Possible pregnancy




 Implanted cardiac devices (ICD, PPM, loop
recorders, or any others)
 Metal heart valve
 History of metal foreign bodies in orbits
 Other implanted metal device which prevents MR
imaging
 Known allergy to Gadolinium contrast
 Claustrophobia
 Weight exceeding 250 kg
 Maximal diameter exceeding 55 cm
 Other contraindications to ICG, including:
 Known allergy to Indocyanine green
 Known allergy to sodium iodine
 Known reaction or allergy to iodine
 Previous diagnosis of a thyroid problem
 Breastfeeding
(Hepatectomy Risk Assessment With Functional Mag-
netic Resonance Imaging - Full Text View -
ClinicalTrials.gov, n.d.)Hepatectomy Risk Assessment
With Functional Magnetic Resonance Imaging - Full
Text View - ClinicalTrials.gov. (n.d.). Retrieved Septem-
ber 30, 2021, from https://clinicaltrials.gov/ct2/show/
NCT04705194
Study procedures (resection arm)
HEPARIM will involve only a minimal deviation from
the routine patient pathway (Fig. 1). In about 3/4 of par-
ticipants the only investigations added for research pur-
poses are the ICG measurements. The rest will not
require a new MRI for surgery planning, and an add-
itional pre-surgery MRI would therefore be performed
for research purposes only. In the small number of PVE/
ALPPS patients, the additional MRI is performed only
for research purposes – see section on study procedures
for the PVE/ALPSS arm.
Recruitment
Patients considered for major liver resection will be
identified at the Hepatobiliary multi-disciplinary team
(MDT) meeting at St James University Hospital Leeds
and contacted by phone. If they agree to finding out
more about the study then an information pack will be
posted to them, including a letter of invitation, the pa-
tient information sheet and an example consent form.
Patients will have at least 3 days to consider this infor-
mation, and after that they will be contacted by the
member of their clinical care team to schedule the base-
line visit.
Baseline visit
Consenting: Formal written consent will be obtained on
the day of the visit. After consenting the participant will
be assigned an anonymous study ID. If they don’t con-
sent to participation, then only the MRI scans requested
by the MDT will be collected and stored in their medical
records, but no research data will be collected.
Questionnaires An initial dataset will be captured in-
corporating the participant’s medical history and up-to-
date investigations. This will be obtained through a com-
bination of interview, review of paper notes and review
of the electronic medical record. An MRI safety screen-
ing form will be administered. If a contraindication to
MRI is found at this point, the visit will be cancelled,
and the participant will be excluded from the study. An
ICG safety questionnaire will be used to exclude partici-
pants with contraindications to ICG use. Participants ex-
cluded from ICG testing at this point will not be
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Fig. 1 Pathway demonstrating patients route through the trial in both the primary surgical and portal vein embolisation arms. Items in blue are
unique to trial patients
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excluded from the study as other measures of liver func-
tion will still be available for analysis of secondary
outcomes.
ICG measurement Participants will be cannulated and
ICG will be administered intravenously as a bolus dose
of 0.5 mg/kg through the cannula. The ICG will be
reconstituted with 5 ml of water for injection for every
25 mg of ICG, leading to a dilution of 5 mg ICG per 1
ml. Serial percutaneous ICG measurements will then be
taken using an ICG clearance meter using a finger clip
device (LiMON; Maquet, Germany). Participants will lie
in the supine position and calibration will be performed
before testing starts. In order to derive absolute ICG
concentrations, we will also take two separate blood
samples of 2.5 mL each, both after ICG injection (pre-
operative). The samples will be processed and stored in
a dedicated facility in the Leeds Institute for Cardiovas-
cular and Metabolic Medicine (LICAMM) and analysed
as a batch at the end of the study.
MRI scanning The MRI will be performed straight after
ICG measurement in 3 T Siemens (Erlangen, Germany)
Magnetom Prisma scanner by radiographers of the de-
partment. The scan will last max 1.5 h and will include
the injection of a standard dose of MRI contrast agent
Gadoxetate 0.1 ml/kg (Primovist, Bayer AG). The same
cannula will be used to administer he MRI contrast as
for the ICG test. Other scans that will be taken in the
same session include precontrast T1- and T2-weighted
anatomical imaging, T2*-mapping, T1-mapping, proton-
density fat fraction and post-contrast T1-weighted ana-
tomical imaging.
Routine clinic visit
After completion of their MRI some participants will re-
quire re-discussion in the MDT and all participants will
attend for a preoperative clinic appointment (see Fig. 1).
A proportion of participants will not progress to surgery
due to clinician or participant choice; these participants
will not be followed up further. But the data that has
already been collected will be used for addressing the
secondary objective.
Intraoperative measurements
Intraoperative measurements of the resected liver seg-
ments will be taken, including weight and volume (mea-
sured using fluid displacement). The weight
measurement is a routine procedure, but the volume
measurement will be done for research purposes only.
In-patient follow-up
Once the participant’s surgery is complete, data obtained
as part of the participant’s standard intra and post-
operative care will be collected. This includes any blood
tests during admission, the characteristics of the oper-
ation, complications and length of stay. Pathology results
will be collected once reported. The ICG test with the
finger-clip device will be repeated postoperatively at bed-
side to determine a reference value for postoperative
liver function. This will be performed on day 1 post-
surgery if feasible. A range of biochemical measures will
be used to calculate postoperative liver function using
the post-operative data set.
90-day follow-up
After discharge all participants who underwent surgery
attend the hospital for a routine post-operative clinic ap-
pointment after 90 days. Data from this appointment will
be collected by the clinical research fellow, including
complications, re-admissions and mortality.
Study procedures (PVE/ALPPS arm)
Participants requiring PVE/ALPPS will be recruited in
the same way as participants in the resection arm. They
will attend the same baseline visit and the routine clinic
visit. Participants may decline the PVE/ALPPS at this
point, or the clinician may decide it is inappropriate at
the clinic appointment. If this occurs and the participant
proceeds to surgery, they will remain in the study. If they
do not proceed to surgery their data will be used to ad-
dress the secondary objectives.
A participant who does proceed to PVE/ALPPS will
attend the hospital for a routine CT scan after the first
stage, and a second research visit will be scheduled at
that point. This visit will proceed in the same manner as
the baseline visit. They will be re-discussed in the MDT
and come for a preoperative clinic appointment. Partici-
pants may be deemed ineligible for surgery, or make the
decision not to proceed with surgery, in which case their
data already collected can feed into the secondary objec-
tives. If they do proceed to surgery, the same intra-
operative and post-operative data will be taken as for the
resection arm.
Management of data and samples
Patient-identifiable data
All physical paperwork with identifiable data will be
stored in a secure location in St James’s Hospital. Elec-
tronic records with identifiable data will be encrypted,
password protected and stored on the hospital’s secure
servers. This includes a single key file containing the link
between patient ID and anonymous study ID. Identifi-
able MRI data will also be stored in the secure Picture
Archiving and Communication System (PACS) of the
radiology department. Identifiable data will not be
accessed by researchers outside of the clinical care team
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and are only retained for quality control, backup, and to
follow-up on any incidental findings.
Pseudo-anonymised study data
Data collected for research purposes will be recorded
using the participant’s anonymous study ID, in a single
file per patient (See Clinical Data points supplementary
file 1). Data will subsequently be transferred to an excel
sheet for statistical analysis. Paper forms will be stored
in a secure location in St James University Hospital.
Electronic data will be stored in a participant study rec-
ord in a secure database on an NHS workstation, and in
password protected network drives set up and main-
tained by University IT. MRI images will be transferred
anonymously from the scanner to the university’s data-
base, where they will be analyzed by a research fellow to
extract the imaging biomarkers. The original MRI data
will be retained the university’s database to enable future
secondary analyses.
Blinding and clinical review of study data
All data collected for the study, except calculated MRI
biomarkers and ICG measurements, are acquired as part
of the routine workup and will therefore be available to
the clinical care team through the participant’s medical
records. ICG liver function measurements will be made
available to the clinical care team to inform management
as appropriate. MRI scans will be reviewed by the radi-
ology department and any unusual findings will be
flagged up to the clinical care team. The research fellows
working on MRI data processing and statistical analysis
will be blinded to the clinical history of the participant
and other function tests.
Long-term data storage
Study documents with identifiable data will be retained
for 10 years in line with the MRC Good Research Prac-
tice guidelines (Medical Research Council 2012) and
then destroyed using the hospital’s confidential waste
management service. During this ten-year period data
will be stored securely on the hospital’s premises and se-
cure electronic systems. Access to the data during this
period will only be available with the consent of one of
the study’s clinical supervisors.
All excel sheets with anonymised study data will be
transferred to a long-term data repository where they
will be maintained for a minimum of 25 years. Source
data for MRI and ICG will be retained indefinitely in a
dedicated imaging data management system hosted by
the University to enable secondary research, educational
use, and data sharing.
Withdrawal of participants
If a participant decides to withdraw their consent to in-
clusion in the study at any point then no further data re-
garding their care will be collected. Should the
participant wish, data collected up until withdrawal of
consent will be destroyed. Participants who lose their
capacity to consent will be treated in the same manner
as if they had withdrawn consent. Previously collected
data will not be destroyed. If a participant is unable to
complete their MRI study for any reason they will auto-
matically be withdrawn from the study. Data collected
until the point of withdrawal will be retained, unless the
participant requests they are deleted,
Blood samples
Blood samples taken after ICG injection at the baseline
visit will be processed in the LICAMM laboratories.
Whole blood and blood plasma will be stored in a secure
sample storage facility within LICAMM with access lim-
ited to LICAMM staff. Samples will be stored in a
freezer and will only be accessed by members of the re-
search team. ICG concentrations will be measured in
batch after finalizing recruitment. The remaining sam-
ples will be stored for a maximum of 5 years to measure
metabolomics data for secondary research. Precise use
will be based on future research priorities. After 5 years
any remaining samples will be destroyed according to
standard LICAMM procedure for sample disposal.
Sample size considerations
Audit
Sample size calculation was informed by an audit of the
preceding year. Between October 2016 and October
2017, a total of 165 patients who met the inclusion cri-
teria underwent surgery at St James’s hospital. 15% of
these patients underwent PVE. Patients undergoing
major liver resection had a rate of PHLF equal to 9%, al-
though the rate of those requiring medical intervention
as a result of their PHLF was only 3.6%. Of the eligible
patients, 67% had an MRI in Leeds after the MDT, and
for a further 7% the MDT requested a local MRI.
For practical and funding reasons the maximum dur-
ation of patient recruitment in HEPARIM was set at 2
years. Based on experience in a pilot study [22], a 50%
recruitment rate was assumed in patients that do not re-
quire an additional MRI visit for research purposes. A
25% recruitment rate was assumed in primary surgery
patients that need an additional MRI, and in PVE/
ALPPS patients.
With these assumptions the maximum number of par-
ticipants over the 2 years is 134, including 122 into the
primary surgery arm and 12 into the PVE/ALPPS arm.
The pilot study also demonstrated that 18% of patients
recruited into the study ultimately did not undergo
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surgery. Hence only 82% of the 122 recruited patients in
the surgery arm will feed into the primary objective, or a
total of 112 including those in the PVE/ALPPS arm.
Power calculation
The power calculation was informed by pilot data in 29
cases, without ICG measurement [22]. The following as-
sumptions were made: (1) patient population values of
FLR-GC follow a log-normal distribution; (2) ICG-C =
10 x FLR-GC + e, with an error variance that reflects un-
certainty in this relationship. The factor 10 encodes the
fact that ICG extraction fractions are an order of magni-
tude higher than for Gadoxetate; (3) error variance is
proportional to true FLR-GC, which invokes heterosce-
dasticity, as observed for the pilot data.
The impact of study size was assessed by simulating a
hypothetical population of 1 million patients and evalu-
ating model robustness to estimate the model beta coef-
ficient of FLR-GC in relation to ICG-C. The relationship
between FLR-GC and ICG-C values is modelled for dif-
ferent error variances ranging from very low precision (4
times the variance of FLR-GC) to good precision (one
quarter the variance of FLR-GC). 10 k samples of 120
patients are drawn with replacement for each of the
three error variances, generating empirical distributions
of the parameters.
Figure 2 shows an example with error variance reflect-
ing low precision. A plot of the model standard errors is
also shown and reveals how optimal precision is around
the largest cluster of data points towards the lower range
of FLR-GC values (1.3 mL/min/kg). At this lowest
Fig. 2 Predicted ICG-C (top) and error in the predicted ICG-C (bottom) for the lowest precision simulated
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precision, the 95% confidence interval for the model beta
coefficient ranges from 9.12 to 10.88 with a median of
10.01 – very close to the exact value of 10. The half-
width of the 95% CI is 8.8% of the exact value, showing
that the sample size is sufficient to obtain reliable beta
coefficients even at the poorest precision simulated.
Discussion
Despite recent changes in surgical practice with in-
creased appetite towards parenchymal preserving sur-
gery for superficial liver tumours, patients with multiple,
deep or perivascular lesions still require major resec-
tional surgery and are not amenable to simple metasta-
sectomy. For these patients PHLF remains a major
concern, the risk of which can potentially be reduced
with a reliable and widely available prediction of post-
operative function. Such a test could also help guide pa-
tient selection for PVE, two stage surgery and ALLPS
and determine which patients do in fact need portal em-
bolisation and which patients can safely proceed straight
to surgery. Once selected for PVE, two stage surgery or
ALPPS, a partial liver function test may improve deci-
sions on the optimal time interval between vascular
intervention and surgery. This can potentially reduce the
risk of further tumour invasion or growth in the waiting
period between the two surgical stages.
Currently available liver function tests are limited ei-
ther by their inability to assess regional segmental liver
function directly or are not widely available. The
HEPARIM trial will examine the ability of a novel MRI-
based technique to accurately measure FLR function and
predict PHLF using FLR-GC as an index of direct re-
gional hepatocyte function. Being an MRI modality, it
can be embedded in the current pre-operative diagnostic
algorithm without the need for additional procedures in
most patients and in a cost-effective manner. Assuming
a positive outcome, HEPARIM will produce strong hy-
potheses that can inform improved management strat-
egies and future clinical trials to test their safety and
efficacy. Potentially, this could include extending the in-
dication for surgery in a subgroup of liver cancer pa-
tients that are currently considered inoperable due to
the high risk of PHLF, but who have a poor prognosis
without surgery.
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